Kodikaz Therapeutic Solutions, Inc.

New York, NY · Biotech · Private

High-throughput screening platform for evaluating horizontal genomic transfer (HGT)-based gene therapies in cancer cells

kodikaz.com →
Grants
$256K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
7
1 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Horizontal genomic transfer technology: Bioengineering DNA sequences for the creation of a non-viral targeted cancer cell specific gene therapy platform$255,831
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1310Pinnacle Medicines——
1311Riptide Bioscience, Inc.——
1312TING THERAPEUTICS LLC——
1313Kodikaz Therapeutic Solutions, Inc.——
1314THERATARGET, INC.——
1315OAKGROVE BIO LLC——
1316MEDVAS CONCEPTS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 7
  • Nucleic Acids For Cell Recognition And Integrationgranted
  • Nucleic Acids For Cell Recognition And Integrationapplication
  • Nucleic Acid-based Delivery Systems And Uses Thereofapplication
  • Receptor-mediated Delivery Of Nucleic Acidsapplication
  • Nucleic Acids For Cell Recognition And Integrationapplication
  • Nucleic Acids For Cell Recognition And Integrationapplication
  • Nucleic Acids For Cell Recognition And Integrationapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.